Malavika Varma

🇨🇦 PGY-2 Internal Medicine @UCalgary. MBBS @AMRITAedu. IMG. Interested in Endocrinology. Passionate about self-care

[Malavika Varma @varma_malavika]

A little late to post. I am so excited to be starting this challenging and rewarding chapter of my life!
Looking forward to training in my favourite city. #carms2023 #externshipcompleted

[Aravind Ganesh @draravindganesh]

🚨 To improve the clinical relevance and completion of cognitive outcomes in studies of stroke, aging and cardiovascular diseases, we propose a new multidimensional and inclusive framework, Major Adverse Cognitive Events (MACE-Cog)! @DrRickSwartz https://t.co/fH2a4tsqyf @CircAHA

[Neurology Journal @GreenJournal]

Futility trials seem feasible in Alzheimer disease-associated dementia, offering a faster, cost-effective alternative to traditional phase 2 randomized-controlled trials: https://t.co/NUTiHbSbMe

[Let's Get Proof @letsgetproof]

We are glad to have supported this important work on stroke care for people with disability/dementia by @draravindganesh and team!

[Aravind Ganesh @draravindganesh]

🚨Brain frailty is associated with worse outcomes after EVT for stroke. Here, we examine sex differences in the assoc of brain frailty with stroke outcomes in the ESCAPE-NA1 trial: https://t.co/nw4C4o1I6M @joachimfladt @mihill68 @mayank_G0 @DCNSNeuro @HotchkissBrain @OBrien_IPH

[Stroke AHA/ASA @StrokeAHA_ASA]

In a mixed method study, the investigators found that physicians encounter profound, multifaceted uncertainty in determining goals of care for patients with disability or dementia after #stroke. https://t.co/Th329wN4aI

[Aravind Ganesh @draravindganesh]

🚨In this intl mixed-methods study led by postdoc Bogna Drozdowska, we found physicians encounter multifaceted uncertainty in determining Goals of Care for ppl with disability or dementia, which may contribute to adverse variability in stroke care @WilliamBetzner @RamkumarRaksha

[Aravind Ganesh @draravindganesh]

🚨Cerebrovascular fibromuscular dysplasia (cFMD) is sometimes seen in patients with stroke/TIA - implications for future risk are unclear. In this cohort study, we found that cFMD was rare but assoc with substantial rates of recurrent stroke & mortality: https://t.co/uIX11DGViq

[Aravind Ganesh @draravindganesh]

🚨The cost & complexity of phase 2 RCTs hinder development of promising AD treatments. We show that futility trials seem feasible in AD dementia, offering a faster cost-effective alternative to traditional ph2 RCTs. CDR-SB may be an optimal primary outcome https://t.co/AtuZVuijFg

[Aravind Ganesh @draravindganesh]

🚨In this detailed analysis of imaging features of small vessel disease (CSVD) in the national COMPASS-ND cohort, we show how CSVD burden contributes to poorer cognition across neurodegenerative conditions and cognitive profiles https://t.co/8fH1wEcKaG @alzdemjournals @ccna_ccnv

[Aravind Ganesh @draravindganesh]

🚨In the current landscape of mixed results from MeVO RCTs, we discuss how consideration of occlusion location, vessel size, and stroke severity can inform MeVO treatment decision-making in practice: https://t.co/Nl3EMKpZb0 @mayank_G0 @rondalun1 @johanna_ospel @SVINJournal

[Aravind Ganesh @draravindganesh]

Kudos to grad students @kadenlam8 @rahulnair320 and Anjana Menon @HotchkissBrain for representing our lab at the 2026 @VAST_training conference with their work on small vessel disease and vascular contributions to dementia!

[Aravind Ganesh @draravindganesh]

🚨In this study of nonstenotic carotid disease in Manitoba, we show the role of plaque thickness+ ulceration in⏫risk of recurrent stroke. Kudos to @nishita_singh3 for building this team from the ground up & to med student Kamran on the paper! @NimaKashani https://t.co/AnlNzFHhiO

[Umberto Pensato @UPensato]

24‐Hour CT Infarct Density modified the effect of Infarct Volume on Outcomes and is independently associated with outcomes in #stroke patients treated with IVT within 4.5 hours. @nishita_singh3 @draravindganesh @AlmekhlafiMa @bijoymenon @JAHA_AHA https://t.co/8vE4F8hgvV

[Aravind Ganesh @draravindganesh]

🚨Infarct density on follow-up imaging determines stroke outcomes independent of infarct volume, as we show in this analysis of @ActRrct, co-led with @UPensato @nishita_singh3: https://t.co/ujzHW0F1FJ. We can automatically determine density standardized across the infarct extent!

[Aravind Ganesh @draravindganesh]

🚨Our meta-analysis on trials of remote ischemic conditioning for mitigation of postoperative cognitive dysfunction and delirium, led by @kadenlam8, is now officially out in press in @journal_aps! @DCNSNeuro @HotchkissBrain

[Umberto Pensato @UPensato]

Redefining the Cerebral Ischemic Core-Penumbra-Oligemia Continuum @StrokeAHA_ASA @johanna_ospel @draravindganesh @nishita_singh3 @AlmekhlafiMa @BroocksGabriel @Libero131087 @DGutierrez__V @NguyenThanhMD @VYogendrakumar @ZiniAndrea @KimBJstroke https://t.co/QmPTYNtaPt

[Circulation @CircAHA]

#ICYMI: Long-Term Risk of Stroke After TIA or Minor Stroke @FaizanK91 @HotchkissBrain @UCalgaryMed
@mihill68 @VYogendrakumar
@draravindganesh @SimonFaHo
@shanfernands @khanevski @rondalun1

[Umberto Pensato @UPensato]

"Time is clot" in #stroke? not in our post hoc analysis of AcT! Kudos to @Katha_MD! @FouziBala @brianhb @lucianacatanese @AlmekhlafiMa @draravindganesh @nishita_singh3 @DCNSNeuro https://t.co/kwuz2vYBp4

[Stroke AHA/ASA @StrokeAHA_ASA]

The April episode of the #StrokeAlert Podcast is now available. In this episode, host @NAsdaghi highlights articles in the April issue of #Stroke and interviews @draravindganesh & @dyavagal.

https://t.co/amc9YsV3V2

[nishita singh @nishita_singh3]

Proud to share our latest in @JournalCJNS 🧠
Secondary analysis of the large phase 3 AcT Trial shows:
➡️Patients treated at PSCs achieve outcomes comparable to CSCs
➡️Despite longer DNTs times,
➡️Tenecteplase may facilitate faster transfer workflows in EVT candidate
OA link👇